No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ARGX240517C380000
- 10.00
- 0.000.00%
15min DelayTrading May 9 12:55 ET
0.00High0.00Low
0.00Open10.00Pre Close0 Volume44 Open Interest380.00Strike Price0.00Turnover29.25%IV2.30%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry10.00Time Value100Contract SizeAmericanOptions Type0.4152Delta0.0249Gamma67.91Leverage Ratio-0.4477Theta0.0307Rho28.20Eff Leverage0.2087Vega
Intraday
- 5D
- 1D
News
Breaking Down Argenx: 12 Analysts Share Their Views
In the latest quarter, 12 analysts provided ratings for argenx (NASDAQ:ARGX), showcasing a mix of bullish and bearish perspectives.The table below offers a condensed view of their recent ratings, show
Argenx Is Maintained at Market Outperform by JMP Securities
Argenx Is Maintained at Market Outperform by JMP Securities
Express News | JMP Securities Maintains Market Outperform on Argenx, Lowers Price Target to $468
Argenx Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 24.84% JMP Securities $471 → $468 Maintains Market Outperform 04/18/2024 38.97% Wedbush → $521
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%
European equities traded in the US as American depositary receipts were trending higher late Friday morning, rising 0.60 to 1,414.50 on the S&P Europe Select ADR Index. With the gain, the index is poi
Express News | Argenx SE : Evercore ISI Cuts Target Price to $437 From $444
Comments
it's number 4, $Amylyx Pharmaceuticals(AMLX.US$ all time low 6.5 USD... hope you can grow and get all FDA approval... it's profitable already...
no 1. $Biogen(BIIB.US$ all time low 2 USD
no 2. $Neurocrine Biosciences(NBIX.US$ all time low 1.9 USD
no 3. $Biohaven(BHVN.US$ all time low 7 USD
no5. $argenx SE(ARGX.US$ all time low 17 USD
And it's not bubble. Of course there are also, biotech companies which are failed. But I think if it's growing into a right directio...
no 1. $Biogen(BIIB.US$ all time low 2 USD
no 2. $Neurocrine Biosciences(NBIX.US$ all time low 1.9 USD
no 3. $Biohaven(BHVN.US$ all time low 7 USD
no5. $argenx SE(ARGX.US$ all time low 17 USD
And it's not bubble. Of course there are also, biotech companies which are failed. But I think if it's growing into a right directio...
2
$Cellectar BioSciences(CLRB.US$ Phase 2
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2...
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2...
36
6
$argenx SE(ARGX.US$
Clinical Disappointment in Phase 3 Study: Pemphigus Vulgaris (PV) and Pemphigus Foliaceus (PF)
Argenx's shares nosedived by 25% due to disappointing results from its Phase 3 study on efgartigimod subcutaneous (SC) for treating severe autoimmune diseases. The study aimed to address pemphigus vulgaris (PV) and pemphigus foliaceus (PF), causing skin blistering.
Unexpectedly Strong Impact of Corticosteroids
The primary setback was the ...
Clinical Disappointment in Phase 3 Study: Pemphigus Vulgaris (PV) and Pemphigus Foliaceus (PF)
Argenx's shares nosedived by 25% due to disappointing results from its Phase 3 study on efgartigimod subcutaneous (SC) for treating severe autoimmune diseases. The study aimed to address pemphigus vulgaris (PV) and pemphigus foliaceus (PF), causing skin blistering.
Unexpectedly Strong Impact of Corticosteroids
The primary setback was the ...
2
Read more
72840290 : you dont pump much do you @Nasser09
Jaguar8 72840290:
Jaguar8 72840290: Spotted huh?
NASSER09OP 72840290: I have another App